| 8.7621 0.042 (0.48%) | 08-21 10:51 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.9 |
1-year : | 12.74 |
| Resists | First : | 9.33 |
Second : | 10.9 |
| Pivot price | 7.57 |
|||
| Supports | First : | 7.7 |
Second : | 6.69 |
| MAs | MA(5) : | 8.05 |
MA(20) : | 7.46 |
| MA(100) : | 7.29 |
MA(250) : | 5.98 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 84.3 |
D(3) : | 81.3 |
| RSI | RSI(14): 70.5 |
|||
| 52-week | High : | 9.61 | Low : | 3.52 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DTIL ] has closed Bollinger Bands are 2.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.99 - 9.03 | 9.03 - 9.06 |
| Low: | 8.21 - 8.25 | 8.25 - 8.29 |
| Close: | 8.44 - 8.5 | 8.5 - 8.56 |
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.
Tue, 18 Aug 2026
Precision BioSciences: Promising HBV Editing Evidence (NASDAQ:DTIL) - Seeking Alpha
Mon, 17 Aug 2026
Precision BioSciences Inc (DTIL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Mon, 10 Aug 2026
Analysts Have Lowered Expectations For Precision BioSciences, Inc. (NASDAQ:DTIL) After Its Latest Results - webull.com
Thu, 06 Aug 2026
Precision Trading with Precision Biosciences Inc. (DTIL) Risk Zones - Stock Traders Daily
Thu, 06 Aug 2026
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire
Thu, 06 Aug 2026
Precision BioSciences (NASDAQ: DTIL) books $10.8M H1 revenue and advances gene editing trials - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 28 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 6.1 (%) |
| Held by Institutions | 65.2 (%) |
| Shares Short | 2,380 (K) |
| Shares Short P.Month | 1,940 (K) |
| EPS | -1.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.95 |
| Profit Margin | -117.1 % |
| Operating Margin | -80.8 % |
| Return on Assets (ttm) | -19.4 % |
| Return on Equity (ttm) | -135.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 1.63 |
| Sales Per Share | 1.63 |
| EBITDA (p.s.) | -1.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -52 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -6.61 |
| PEG Ratio | 0 |
| Price to Book value | 2.95 |
| Price to Sales | 5.34 |
| Price to Cash Flow | -4.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|